Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis
Background: Clinical efficacy of zilucoplan has been demonstrated in a 12-week, placebo-controlled, phase III study in patients with acetylcholine receptor autoantibody-positive generalised myasthenia gravis (gMG). However, placebo-controlled zilucoplan data past 12 weeks are not available. Objectiv...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
SAGE Publishing
2024-09-01
|
| 叢編: | Therapeutic Advances in Neurological Disorders |
| 在線閱讀: | https://doi.org/10.1177/17562864241279125 |